Clinical trials: G6PD Deficiency
Paludism
Evaluation of the STANDARD G6PD Rapid Test for Assaying the Enzymatic Activity of G6PD in French Guiana
In French Guiana, malaria is endemic and two species predominate: P. falciparum and P. vivax. The treatments against Plasmodium vivax malaria are: nivaquine for 3 days against circulating blood parasites and primaquine for 14…
- Trial name
- G6PD facile (NCT04698980)
- Testing
- blood samples (venous and capillary at the fingertip)
- Where
- French Guiana
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Malaria
Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with dihydroartemisinin-piperaquine in G6PD deficient males.
- Trial name
- SAFEPRIM-II (NCT02654730)
- Testing
- Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
- Where
- The Gambia
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Hyperbilirubinemia, Jaundice
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia
The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia to patients who never developed a significant bilirubin level.
- Trial name
- NCT00383318
- Testing
- Gene mutation sample
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Pediatrix
Malaria Vivax, Malaria Falciparum
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria…
- Conditions
- Malaria Vivax, Malaria Falciparum, Plasmodium Vivax, Plasmodium Falciparum
- Trial name
- PvSTATEM (NCT06923592)
- Testing
- PvSeroTAT, Control
- Where
- 2 sites in Ethiopia, Madagascar
- Volunteers
- 19,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Vivax Malaria, G6PD Deficiency
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
A clinical study to assess the safety and efficacy of alternative regimens of primaquine for radical cure of vivax malaria in glucose 6-phosphate dehydrogenase (G6PD) deficient. G6PD deficient patients with P.
- Trial name
- NCT03529396
- Testing
- Chloroquine, Primaquine
- Where
- 2 sites in Brazil
- Volunteers
- 106 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Malaria, Severe Malaria
Examination of Protective Factors Against Severe Malaria
This study, sponsored by the National Institutes of Health and the University of Bamako in Mali, Africa, will examine factors that may protect against progression of malaria from mild to severe disease.
- Trial name
- NCT00342043
- Where
- Mali
- Volunteers
- 4,850 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Glucose-6-Phosphate Dehydrogenase Deficiency
Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is prevalent and add a burden on families in Egypt and Middle East due to lifelong diet restriction, non-fava beans diet is main food for most families in the region and parents…
- Trial name
- NCT02498340
- Testing
- non- fava beans
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
G6PD, G6PD Deficiency
Comparative Evaluation of the FINDER Instrument and FINDER G6PD Cartridge in Adults and Neonates
A prospective clinical study to compare the clinical performance of the FINDER™ Instrument and the G6PD assay to an FDA cleared instrument/reagent combination in adult and neonate populations.
- Trial name
- NCT04146246
- Testing
- G6PD assay
- Where
- 3 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Baebies, Inc.
Malaria, Vivax
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
This is a prospective, open-label, multicenter, non-comparative, single arm study of pediatric subjects with Plasmodium vivax (P. vivax) malaria, aged 6 months to <16 years of age. A total of 60 subjects will be enrolled.
- Trial name
- NCT02563496
- Testing
- Tafenoquine, Chloroquine
- Where
- 4 sites in Colombia, Vietnam
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Malaria, Mass Drug Administration
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination.
- Conditions
- Malaria, Mass Drug Administration, Myanmar, Plasmodium Vivax
- Trial name
- NCT06392152
- Testing
- Focal Mass Drug Administration with Primaquine
- Where
- Burma
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pyae Linn Aung
Malaria, Falciparum, G6PD Deficiency
Safety and Tolerability of Low Dose Primaquine
In Cambodia, falciparum is becoming more difficult to treat because drugs are becoming less effective. The investigators can help to try to prevent the spread of this resistant malaria by adding a drug that will make it more…
- Trial name
- NCT02434952
- Testing
- Dihydroartemisinin piperaquine (DHA PP), Primaquine
- Where
- Cambodia
- Volunteers
- 109 people
- Sponsor
- Malaria Consortium
Malaria
A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan
This is a randomized controlled trial to assess the efficacy and safety of the national malaria treatment guidelines, asses the efficacy and safety of artesunate and sulphadoxine - pyrimethamine (AS+SP) for treatment in…
- Trial name
- MalTreSu (NCT02592408)
- Testing
- ASP, SDPQ, 14DPQ
- Where
- 2 sites in Sudan
- Volunteers
- 320 people
- Sponsor
- Menzies School of Health Research
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
The proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease.
- Trial name
- SCOPE (NCT05879224)
- Testing
- Revised case management package
- Where
- 6 sites in Indonesia
- Volunteers
- 2,999 people
- Sponsor
- Menzies School of Health Research
Glucose-6-Phosphate Dehydrogenase Deficiency
Evaluation of Different G6PD Testing Platforms
In this study the investigators propose to evaluate the performance of several G6PD testing platforms.
- Trial name
- NCT02104518
- Where
- Indonesia
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- PATH
Vivax Malaria
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
This will be a single-arm observational cohort study. Malaria patients with Plasmodium vivax and meeting study inclusion criteria, who give consent to be enrolled in the study, will have their G6PD status measured by the…
- Trial name
- GAP (NCT02876549)
- Testing
- Chloroquine, Primaquine 0.25 mg/kg/day, Primaquine 0.75 mg/kg weekly
- Where
- Afghanistan
- Volunteers
- 1,000 people
- Sponsor
- University of Oxford
Malaria, Vivax, G6PD Deficiency
Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
This is an observational study carried out in Brazil in patients with P. vivax malaria. The study will be carried out in the municipalities of Manaus (state of Amazonas) and Porto Velho (state of Rondônia).
- Trial name
- Trust (NCT05096702)
- Testing
- Tafenoquine, Primaquine
- Where
- 41 sites in Brazil
- Volunteers
- 16,000 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia
OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in…
- Conditions
- Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia, Hemolytic Disease of Newborn
- Trial name
- NCT00004381
- Testing
- tin mesoporphyrin
- Where
- 2 sites in United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Malaria, Vivax
Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
The goal of this study is to evaluate the operational feasibility of using a new treatment algorithm for Malaria Vivax in Peru. The implementation package includes the following interventions: A revised vivax treatment algorithm…
- Trial name
- NCT05361486
- Testing
- Tafenoquine (TQ)
- Where
- Peru
- Volunteers
- 187 people
- Sponsor
- Medicines for Malaria Venture
Hemolytic Disorders, Gallstones
The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders
It is well established that hemolytic diseases predispose patients to the development of pigment gallstones. Gallstones are noted in at least 5% of children under the age of 10 years, increasing to 40-50% in the second to fifth…
- Trial name
- NCT02472509
- Testing
- Ursodeoxycholic Acid
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Shaare Zedek Medical Center